|Bid||0.5000 x 800|
|Ask||0.5170 x 2200|
|Day's Range||0.4959 - 0.5200|
|52 Week Range||0.4900 - 8.5000|
|Beta (5Y Monthly)||1.43|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 16, 2022 - Mar 21, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.14|
Celldex (CLDX) posts interim data from the phase Ib study evaluating barzolvolimab in patients with moderate to severe chronic spontaneous urticaria. Shares down.
Graybug's (GRAY) board of directors is set to review strategic options focused on maximizing shareholder value, including a potential sale of the company. Shares rise.
Cybin (CYBN) receives a "may proceed letter" and IND application clearance from the FDA for a phase I/IIa study evaluating CYB003 for potential treatment of major depressive disorder. Shares up.